Instil Bio, Inc.

TIL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-71.4M $-74.1M $-156.1M $-223.2M $-156.8M $-37.7M
Depreciation & Amortization $534.0K $3.6M $4.8M $6.0M $2.8M $256.0K
Depreciation $500.0K $3.6M $4.8M $6.0M $2.7M $300.0K
Amortization
Stock-Based Compensation $8.7M $17.3M $18.2M $30.4M $26.2M $1.7M
Net Cash from Operating Activities $-36.6M $-55.7M $-82.0M $-180.2M $-122.1M $-29.6M
Investing Activities
Capital Expenditures $0 $20.7M $84.6M $57.8M $50.8M
Business Acquisitions $0 $306.0K
Net Cash from Investing Activities $25.5M $54.0M $41.1M $114.5M $-474.4M $-51.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $7.3M $1.8M $8.1M $71.9M $393.2M $313.0M
Net Change in Cash
Free Cash Flow $-55.7M $-102.7M $-264.8M $-180.0M $-80.4M